🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06924996
Enrolling by invitation Observational

Efficacy and Safety of Endovascular Thrombectomy in Acute Ischemic Stroke With Posterior Circulation Large Infarct

NCT06924996 · tracked via the Priya Life Science China tracker
Sponsor
Feng Gao
Phase
Observational
Started
2023-01-01
Last updated
2025-04-13

Condition(s) studied

Acute Basilar Artery OcclusionPosterior Circulation Large Infarct

Investigational drug(s) / intervention(s)

Endovascular Thrombectomy (EVT)

Endovascular Thrombectomy (EVT): A maximum of six attempts to retrieve the thrombus in a single vessel can be made with any Solitaire AB/FR device or aspiration. In case an atherosclerotic lesion is found underlying the occlusive lesion, angioplasty and subsequent stenting through detachment of the Solitaire device will be allowed

Study summary

The purpose of this study is to evaluate whether endovascular thrombectomy (EVT) combined with best medical management (BMM) leads to better functional outcomes than BMM alone in patients with acute basilar artery occlusion with posterior circulation large infarct.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age 18-80 years old; 2. Acute ischemic stroke in the posterior circulation, the onset of stroke (or last well known) to the enrollment time within 24 hours; 3. CTA/MRA/DSA confirmed acute basilar artery occlusion; 4. Posterior circulation large infarct: NCCT or DWI showed pc-ASPECTS ≤ 5 points, or pontine midbrain index (PMI) ≥ 3 points; 5. NIHSS score ≥10 points after the onset of the stroke and before enrollment; 6. Able to live independently before the onset of the disease (mRS score ≤2 points); 7. The subject or legal representative is able to sign the informed consent form. Exclusion Criteria: 1. Intracranial hemorrhage (except microhemorrhage) on CT/MRI ; 2. CT/MRI revealed large infarction in the cerebellar hemisphere, with significant mass effect causing compression of the fourth ventricle or brainstem; 3. CT or MRI showed bilateral complete thalamic infarction; 4. Occlusion of anterior and posterior circulation arteries confirmed by CTA/MRA/DSA; 5. The presence of intracranial tumors (except for small meningiomas and cerebral aneurysms with a diameter of \<3mm); 6. Patients with known or highly suspected chronic basilar artery occlusion.; 7. Known severe allergy to contrast agents (except for mild rash); 8. Refractory hypertension (defined as systolic blood pressure \> 185 mmHg or diastolic blood pressure \>110 mmHg) that cannot be controlled by drug therapy; 9. Known pregnant or lactating females, or positive pregnancy test before enrollment; 10. Acute cerebral infarction within 48 hours after cardiovascular and cerebrovascular intervention or major surgery (patients more than 48 hours can be enrolled).

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Beijing Tiantan Hospital Beijing Beijing Municipality

More Feng Gao trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06924996 on ClinicalTrials.gov ↗ ← All trials in China